We invite Business Development executives to this unique and important “Innovative Business Opportunities for NF” meeting, which will be held on the afternoon of June 9th (2 – 4 p.m.). The meeting will kick off with a presentation from Foundation President and Chief Scientific Officer, Annette Bakker, during which she will highlight CTF’s activities in its relations with industry — bridging academia with pharma/biotech, and the critical need for drugs to enter the pipeline. Her overview will be followed by a compelling presentation by Foundation consultant, David Lapidus, on the NF market model.
A panel discussion will then follow, moderated by Randall Stanicky, RBC Managing Director, Global Equity Research – Specialty Pharmaceuticals. Through the expertise and experience of our panelists, the goal will be to clearly affirm that:
Innovative models are applied in industry to better match patient needs with business opportunities – Mark DeSouza, PhD, CEO, desouzatech
Other successful disease foundations have adopted business models that efficiently translate research findings into clinical benefit – Margaret Anderson, Executive Director, FasterCures
There is a well-defined clinical need and a path to approval for NF – REiNS (“Response Evaluation in Neurofibromatosis and Schwannomatosis”), Scott Plotkin, MD, PhD, Director, Neurofibromatosis Clinic, Massachusetts General Hospital and Chairperson, REiNS
It is possible to make an NF business case – David Lapidus, Principal, LapidusData LLC
Companies have interest in NF – Gideon Bollag, PhD, CEO, Plexxikon
The investor’s position on rare disease and NF – Sarah Nayeem, MD, Principal, New Enterprise Associates
Registration fee – $100, includes entry to the Tuesday session featuring presentations on preclinical and clinical testing of NF-relevant molecules. Free of charge for registered NF Conference attendees.
For more information and to register, contact Patrice Pancza at ppancza@ctf.org.
For more information on the NF Conference, click here.
